A part of Watch Media

MedWatchSaturday4 February 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
12/10/2022at 07:35

Sonova is testing new model for raising listing prices

The hearing aid sector usually only raises prices when bringing out new technology, but on a challenging market, even the world’s biggest hearing aid manufacturer has to look for new methods.
Sonova launched a new product platform, Phonak Lumity, in August 2022 | Photo: Sonova / PR
by marketwire, translated by daniel pedersen

A large increase in manufacturing costs due to more expensive raw materials and components, as well as higher energy expenses, have led a number of companies to finetune sales prices to offset negative effects.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters

Get full access for you and your coworkers

Start a free company trial today

Related articles:

  • Photo: Sonova / PR

    Consumers have not pivoted to cheaper alternatives, Sonova CEO says

    For subscribers

  • Photo: Sonova / PR/Daniel Hager Photography & Film

    Sonova CEO had hoped for a "less dynamic" post-pandemic period

    For subscribers

  • Sonova eyes bright future despite gloomy markets

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Nu mangler kun en endelig vedtagelse i EU-Parlamentet, før lovforslag om at udskyde deadlines for nye krav til medicinsk udstyr. er en realitet. | Foto: Thomas Borberg/Ritzau Scanpix
Medtech

Another hurdle overcome in delaying MDR deadline

EU member countries have voted unanimously to adopt an EU Commission proposal to stagger the implementation of the new Medical Device Regulation. Now, only the EU Parliament’s vote remains. 
  • Asensus Surgical wins CE Mark for intelligent surgical unit under MDR rules
  • EU Commission to give more time for MDR transition

For subscribers

Foto: Stine Tidsvilde
Pharma & biotech

Novo Nordisk hopes to retain employees with share gift

For subscribers

Foto: MedWatch
Other

Top news from MedWatch this week

Luja can potentially solve a long-lived UTI problem for people who need help with bladder control issues by using new micro-hole technology
Medtech

Coloplast to set new treatment standard with Luja – but keeps sales goal under wraps

For subscribers

Foto: Coloplast/pr
Medtech

Coloplast launches male catheter featuring new technology

For subscribers

Foto: Coloplast / Pr
Medtech

Coloplast's bottom line disappoints in otherwise strong report

For subscribers

Further reading

Foto: Novo Nordisk / Pr
Pharma & biotech

Novo Nordisk CEO rakes in cash in record year

Being at the top of Denmark’s most valuable company is lucrative, Novo Nordisk reveals in its annual report – and Chief Executive Lars Fruergaard Jørgensen is making a killing there.

For subscribers

Foto: Fabian Bimmer/Reuters/Ritzau Scanpix
Pharma & biotech

Supply issues to continue in 2023, reports Novo Nordisk

Investing massively into increasing production capacity, Novo Nordisk hopes to increase its drug supply, though 2023 will still see ”periodic supply constraints,” informs Novo CFO Karsten Munk Knudsen.

For subscribers

Foto: Stine Tidsvilde
Pharma & biotech

Novo Nordisk hopes to retain employees with share gift

All Novo Nordisk employees have been offered 37 restricted stock units, which can be turned into real B shares in Aug. 2026.

For subscribers

Latest news

  • Top news from MedWatch this week – 3 Feb
  • Coloplast to set new treatment standard with Luja – but keeps sales goal under wraps – 3 Feb
  • China accepts regulatory filing for ALK allergy tablet – 3 Feb
  • Another hurdle overcome in delaying MDR deadline – 3 Feb
  • Dupixent becomes ninefold blockbuster – 3 Feb
  • ALK forecasts lower growth in 2023 than strong 2022 result – 3 Feb
  • Unilabs and Siemens Healthineers enter million-euro strategic partnership – 3 Feb
  • Coloplast launches male catheter featuring new technology – 3 Feb
  • Novo Nordisk hopes to retain employees with share gift – 3 Feb
  • Coloplast's bottom line disappoints in otherwise strong report – 3 Feb
See all

Jobs

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Medical Advisor (Metabolism)

  • Commercial Director

  • Regulatory Affairs Professional

  • Experienced Patent Counsel

  • Lead Data Architect

  • Sr. Director, Drug Safety Physician

  • Application Manager

  • Application Manager

  • Supply Chain Manager

  • Clinical Operational Associate

  • Senior Clinical Project Manager

  • Senior Health Economics and Outcomes Research (HEOR) Manager

See all jobs

Jobs

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Medical Advisor (Metabolism)

  • Commercial Director

  • Regulatory Affairs Professional

  • Experienced Patent Counsel

  • Lead Data Architect

  • Sr. Director, Drug Safety Physician

  • Application Manager

  • Application Manager

  • Supply Chain Manager

  • Clinical Operational Associate

  • Senior Clinical Project Manager

  • Senior Health Economics and Outcomes Research (HEOR) Manager

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge